Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program
Beam Therapeutics (Nasdaq: BEAM) will host an investor webcast on Tuesday, February 24, 2026 at 8:00 a.m. ET to announce its fourth quarter and full year 2025 financial results and a new liver-targeted genetic disease program.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Beam Therapeutics (Nasdaq: BEAM) will host an investor webcast on Tuesday, February 24, 2026 at 8:00 a.m. ET to announce its fourth quarter and full year 2025 financial results and a new liver-targeted genetic disease program.
The live webcast will be available in the investor section of the company's website and will be archived for 60 days after the presentation.
Details
News Market Reaction – BEAM
On Feb 24, the first trading day after this news, BEAM closed 13.98% above the previous close. That session’s volume was 2.6x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Feb 24 session.
Key Figures
- Webcast date
- February 24, 2026
- Investor webcast for Q4 and full-year 2025 results
- Webcast time
- 8:00 a.m. ET
- Start time of BEAM’s investor webcast
- Archive duration
- 60 days
- Webcast replay availability on company website
Previous Conferences,earnings Reports
-
Announced Q3 2024 earnings call and ASH abstracts webcast timing.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
investor webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will announce its fourth quarter and full year 2025 financial results and a new liver-targeted genetic disease program on an investor webcast on Tuesday, February 24, 2026, at 8:00 a.m. ET.
The live webcast will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Contact:
Holly Manning
Beam Therapeutics
hmanning@beamtx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.